Israel, Tel Aviv
Prof. Dr. David Sarid, an Oxford-trained uro-oncology specialist with 30+ publications, leads the targeted therapy program at Sourasky Medical Center. The consultation with therapy planning may cost around $950, typically including genomic testing and multidisciplinary team review. The center offers Lutetium-177 PSMA therapy – one of few worldwide combining diagnostic PET/CT with targeted radionuclide treatment. JCI-accredited with a 90% oncology success rate, the hospital provides access to experimental therapies via clinical trials.